Uwe Rix

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Uwe Rix, Oliver Hantschel, Gerhard Dürnberger et al. · Blood · 2007 · 663 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

Jiannong Li, Uwe Rix, Bin Fang et al. · Nature Chemical Biology · 2010 · 283 citations · Full text

Medicine, Biochemistry, Oncology +13

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Oliver Hantschel, Uwe Rix, Uwe Schmidt et al. · Proceedings of the National Academy of Sciences · 2007 · 282 citations · Full text

Medicine, Molecular Biology, Oncology +16

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

Lily L. Remsing Rix, Uwe Rix, Jacques Colinge et al. · Leukemia · 2008 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

Emir Hadzijusufovic, Karin Albrecht-Schgoer, K. Huber et al. · Leukemia · 2017 · 155 citations · Full text

Veterinary Medicine, Molecular Medicine, Pharmacotherapy +13